Introduction: In Radiopharma, Distribution Is Part of the Product
GE HealthCare’s $945 million agreement to acquire SOFIE Biosciences looks small next to the day’s multibillion-dollar software and logistics deals, but strategically it targets one of healthcare’s fastest-growing infrastructure bottlenecks: producing and delivering short-lived radioactive imaging drugs close enough to patients for them to remain usable.
The company is not merely buying a portfolio of molecules. It is buying a U.S. manufacturing and distribution network built around positron emission tomography, or PET, radiopharmaceuticals. SOFIE operates 15 contract-manufacturing sites with 21 cyclotrons, plus a theranostics-focused development and manufacturing site. That network gives GE HealthCare physical proximity to hospitals and imaging centers — the “final mile” that becomes unusually important when the product itself decays over time.
The deal also gives GE HealthCare U.S. rights to FAPI-74, a Phase III PET imaging agent with potential use across multiple cancers. GE HealthCare already holds rights outside the United States. The acquisition therefore combines pipeline economics with manufacturing infrastructure.
What Happened
GE HealthCare announced on October 5 that it signed a definitive agreement to acquire privately held SOFIE Biosciences from Trilantic North America for $945 million in cash. The companies expect the transaction to close in the first half of 2027, subject to regulatory approvals and customary conditions.
After closing, SOFIE will become part of GE HealthCare’s Pharmaceutical Diagnostics segment. Management says SOFIE will continue manufacturing products for other radiopharmaceutical companies as well, rather than becoming an exclusively captive network.
The acquisition adds 15 U.S. CMO sites, 21 cyclotrons and a CDMO site focused on theranostics. It also brings U.S. rights to FAPI-74, which is currently in Phase III development and is being evaluated as a potentially broad cancer-imaging tracer.
Why the ‘Final Mile’ Is Different in Radiopharma
Most pharmaceutical distribution is designed around inventory durability. A conventional pill or injectable can often be manufactured centrally, stored, shipped and held in inventory. PET radiopharmaceuticals are different because the radioactive isotopes used in many tracers have short half-lives.
That changes the economics of the supply chain. Manufacturing has to occur close to the patient. Production schedules must align with imaging appointments. Transportation delays can destroy usable dose value. Quality control and regulatory compliance must happen under tight time constraints.
Cyclotrons are therefore not just factories. They are nodes in a time-sensitive distribution network. Owning or controlling access to more nodes can improve reliability, expand geographic coverage and make it easier to launch new tracers.
For GE HealthCare, that network complements an installed base of PET scanners, digital workflow tools and other imaging infrastructure. The company can potentially participate in more steps of the diagnostic pathway instead of selling only the scanner or only the tracer.
Why FAPI-74 Matters
FAPI-74 targets fibroblast activation protein, which is expressed in the tumor microenvironment across a range of cancers. The attraction of FAP-targeted imaging is the possibility of visualizing multiple tumor types with a common biological target.
FAPI-74 is still experimental in the United States. Phase III status means the program is advanced, but it does not guarantee FDA approval. Investors should therefore treat the pipeline value as optionality rather than approved commercial revenue.
If the product succeeds, however, the combination of rights and distribution infrastructure could be powerful. GE HealthCare would control U.S. rights to the tracer while also owning a network capable of producing and delivering PET doses. That can reduce launch friction and potentially improve adoption.
Market Impact: Radiopharma Is Becoming a Strategic Asset Class
The transaction fits a broader wave of deal activity in radiopharmaceuticals. Companies are investing in radioactive diagnostic and therapeutic products because precision oncology increasingly depends on molecular imaging and targeted treatment.
The strategic bottleneck is not only drug discovery. Manufacturing capacity, isotope supply, local distribution and specialized regulatory operations are equally important. That is why infrastructure can command significant value even when many individual drugs are still in development.
GE HealthCare already participates in radiopharma through products such as Flyrcado, an FDA-approved PET agent for evaluating coronary artery disease and myocardial ischemia. SOFIE expands that footprint and increases exposure to oncology imaging.
The deal also reflects a larger trend toward vertical integration in healthcare technology. Equipment makers increasingly want recurring revenue from consumables, software and services that run through the installed base. A PET scanner generates capital-equipment revenue when sold. Radiopharmaceutical doses can create recurring revenue every time the scanner is used.
Key Data and Timeline
The purchase price is $945 million in cash. SOFIE operates 15 U.S. contract-manufacturing sites and 21 cyclotrons, as well as a theranostics-focused CDMO site. The transaction is expected to close in the first half of 2027.
The deal gives GE HealthCare U.S. rights to FAPI-74 while the company already owns rights outside the United States. FAPI-74 remains in Phase III development, so any commercial timing depends on successful clinical results, regulatory submission and FDA review.
SOFIE is expected to remain a supplier to third parties after closing, which is strategically important. If GE HealthCare can preserve outside customers, the network can generate manufacturing revenue while also supporting GE HealthCare’s own tracer portfolio.
Market Debate: Vertical Integration or Capital-Intensive Complexity?
The bullish case is that GE HealthCare is building a differentiated ecosystem. Imaging hardware, radiopharmaceuticals, manufacturing, distribution and digital workflow can reinforce one another. Hospitals may prefer a supplier that can solve the full operational problem rather than deliver a single product.
The skeptical case is that radiopharma infrastructure is operationally demanding. Cyclotron networks require capital, specialized staff and strict compliance. Utilization matters: fixed infrastructure is attractive when dose volumes grow, but returns can disappoint if pipelines fail or local demand remains uneven.
There is also channel conflict. SOFIE manufactures products for multiple companies. GE HealthCare says that will continue, but competitors may reconsider how much manufacturing they want to place with a network owned by another large imaging company.
Risks
Clinical and regulatory risk around FAPI-74 is the most obvious. Phase III programs can fail, and successful trials still require regulatory approval. The second risk is integration. GE HealthCare must preserve SOFIE’s operational reliability while integrating it into a much larger organization.
The third risk is utilization. A broad manufacturing network needs sufficient volume to justify fixed costs. The fourth is isotope and supply-chain reliability. Radiopharmaceutical businesses can be constrained by isotope availability, equipment downtime and transportation disruption.
What to Watch Next
Investors should follow FAPI-74 Phase III results and any regulatory filing timeline. GE HealthCare’s future reporting should also reveal whether it provides revenue, margin or capital-expenditure targets for the acquired network.
Another key signal will be third-party customer retention. If SOFIE continues winning external manufacturing contracts after ownership changes, the network may prove to be a neutral infrastructure asset rather than only an internal production arm.
Finally, watch for additional radiopharma transactions. If competitors continue buying manufacturing networks, isotope assets and targeted-therapy platforms, the sector’s infrastructure scarcity may become even more valuable.
Conclusion
GE HealthCare is paying $945 million for more than a pipeline asset. It is buying the physical network required to make PET radiopharmaceuticals available where and when patients need them.
That distinction matters because radiopharma is one of the few areas in healthcare where manufacturing geography is part of the product. If FAPI-74 succeeds and PET-based oncology continues to expand, SOFIE’s cyclotron footprint could become a strategic distribution advantage. If clinical programs disappoint or utilization stays low, the same infrastructure can become an expensive fixed-cost base. The value of the deal will therefore be measured in both molecules and miles.